The global oncology market is experiencing a seismic shift with the emergence of HER2 low cancers as a distinct and highly valuable therapeutic target. This market segment, previously overlooked and underserved, has rapidly evolved into one of the most promising areas of cancer drug development. The recognition of HER2 low expression as a actionable target has unlocked...